Autologous ADIpose derived stromal vascular fraction ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease1

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-001948-21-FR
(EUCTR)
03/09/201915/05/2019Double-blind randomised placebo controlled study evaluating local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN’s fistulas.Double-blind randomised placebo controlled study evaluating local co-administration of autologous ADIpose derived stromal vascular fraction with microfat for refractory perianal CROHN’s fistulas. - ADICROHN-II Crohn’s disease;Therapeutic area: Diseases [C] - Immune System Diseases [C20]Product Name: autologous ADIpose derived stromal vascular fraction
Product Code: ADSVF
Trade Name: vialebex 200mg
Product Name: VIALEBEX
Product Code: SERUM ALBUMINE 5%
INN or Proposed INN: ALBUMINE HUMAINE
Other descriptive name: HUMAN ALBUMIN AS MACROAGGREGATES
Trade Name: serum physiologique 0.9 %
Product Name: chlorure de sodium
INN or Proposed INN: CHLORURE DE SODIUM
Other descriptive name: SODIUM CHLORIDE
ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLENULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Phase 2France